BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18027843)

  • 1. Electromagnetic fields alter the expression of estrogen receptor cofactors in breast cancer cells.
    Girgert R; Gründker C; Emons G; Hanf V
    Bioelectromagnetics; 2008 Apr; 29(3):169-76. PubMed ID: 18027843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of tamoxifen resistance in breast cancer cells by ELF electromagnetic fields.
    Girgert R; Schimming H; Körner W; Gründker C; Hanf V
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1144-9. PubMed ID: 16168388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer.
    Cohen I; Maly B; Simon I; Meirovitz A; Pikarsky E; Zcharia E; Peretz T; Vlodavsky I; Elkin M
    Clin Cancer Res; 2007 Jul; 13(14):4069-77. PubMed ID: 17634531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
    Pennanen PT; Sarvilinna NS; Ylikomi TJ
    Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Response to tamoxifen in estrogen receptor-positive cell line MCF-7 is independent of p53 expression].
    Shtam TA; Pantina RA; Varfolomeeva EIu; Filatov MV
    Vopr Onkol; 2007; 53(2):194-9. PubMed ID: 17663174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
    Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
    Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
    Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of protein expression in magnetic field-treated human glioma cells.
    Kanitz MH; Witzmann FA; Lotz WG; Conover D; Savage RE
    Bioelectromagnetics; 2007 Oct; 28(7):546-52. PubMed ID: 17570505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
    Zhao W; Zhang Q; Kang X; Jin S; Lou C
    Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
    Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
    J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells.
    Yde CW; Clausen MP; Bennetzen MV; Lykkesfeldt AE; Mouritsen OG; Guerra B
    Anticancer Drugs; 2009 Sep; 20(8):723-35. PubMed ID: 19584708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.
    Auer D; Reimer D; Porto V; Fleischer M; Roessler J; Wiedemair A; Marth C; Müller-Holzner E; Daxenbichler G; Zeimet AG
    Breast Cancer Res Treat; 2009 Jul; 116(1):103-11. PubMed ID: 18618240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.
    Owusu C; Buist DS; Field TS; Lash TL; Thwin SS; Geiger AM; Quinn VP; Frost F; Prout M; Yood MU; Wei F; Silliman RA
    J Clin Oncol; 2008 Feb; 26(4):549-55. PubMed ID: 18071188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells.
    Girgert R; Hanf V; Emons G; Gründker C
    J Pineal Res; 2009 Aug; 47(1):23-31. PubMed ID: 19522736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
    Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
    Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer.
    Cappelletti V; Gariboldi M; De Cecco L; Toffanin S; Reid JF; Lusa L; Bajetta E; Celio L; Greco M; Fabbri A; Pierotti MA; Daidone MG
    Endocr Relat Cancer; 2008 Jun; 15(2):439-49. PubMed ID: 18508997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
    Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
    Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.